Suppr超能文献

植物源寄生虫疫苗:对抗恰加斯病的仿生学策略。

Plant-made vaccines against parasites: bioinspired perspectives to fight against Chagas disease.

机构信息

Grupo de Inmunología & Vacunología. Centro de Investigaciones Biológicas del Noroeste, S.C. (CIBNOR), Instituto Politécnico Nacional 195, Playa Palo de Santa Rita Sur, La Paz, B.c.s. C.p., México.

CONACYT- Centro de Investigaciones Biológicas del Noroeste, S.C. (CIBNOR), Instituto Politécnico Nacional 195, Playa Palo de Santa Rita Sur, La Paz, B.c.s. C.p, México.

出版信息

Expert Rev Vaccines. 2021 Nov;20(11):1373-1388. doi: 10.1080/14760584.2021.1893170. Epub 2021 Mar 5.

Abstract

: Three decades of evidence have demonstrated that plants are an affordable platform for biopharmaceutical production and delivery. For instance, several plant-made recombinant proteins have been approved for commercialization under good manufacturing practice (GMP). Thus far, plant-based vaccine prototypes have been evaluated at pre- and clinical levels. Particularly, plant-made vaccines against parasitic diseases, such as malaria, cysticercosis, and toxoplasmosis have been successfully produced and orally delivered with promising outcomes in terms of immunogenicity and protection. The experience on several approaches and technical strategies over 30 years accounts for their potential low-cost, high scalability, and easy administration.: This platform is an open technology to fight against Chagas disease, one of the most important neglected tropical diseases worldwide.: This review provides a perspective for the potential use of plants as a production platform and delivery system of recombinant antigens, analyzing the advantages and limitations with respect to plant-made vaccines produced for other parasitic diseases. Plant-made vaccines are envisioned to fight against Chagas disease and other neglected tropical diseases in those countries suffering endemic prevalence.

摘要

三十年来的证据表明,植物是生物制药生产和输送的一种经济实惠的平台。例如,已经有几种植物制造的重组蛋白在良好生产规范 (GMP) 下获得了商业化批准。到目前为止,基于植物的疫苗原型已经在临床前和临床阶段进行了评估。特别是,针对寄生虫病(如疟疾、囊尾蚴病和弓形体病)的植物制造疫苗已经成功生产,并以有前途的免疫原性和保护效果进行了口服给药。三十年来,在几种方法和技术策略方面的经验证明了它们具有低成本、高可扩展性和易于管理的潜力。

该平台是一种针对恰加斯病(全球最重要的被忽视热带病之一)的开放式技术。

本文综述了植物作为一种生产平台和重组抗原输送系统的潜在用途,分析了针对其他寄生虫病生产的植物制造疫苗的优势和局限性。预计植物制造的疫苗将在那些流行地方性疾病的国家用于对抗恰加斯病和其他被忽视的热带病。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验